Krause J R, Shahidi-Asl Mahnaz
Department of Pathology, Tulane Health Sciences Center, New Orleans, LA 70112, USA.
J Cell Mol Med. 2003 Oct-Dec;7(4):494-512. doi: 10.1111/j.1582-4934.2003.tb00254.x.
The non-Hodgkin's lymphomas encompass a wide spectrum of hematologic neoplasms that exhibit different clinical and biological features. Lymphomas classically have been initially assessed based on their cytologic and histologic features. Morphology alone is often inadequate as similar appearing neoplasms may be immunophenotypically and molecularly heterogeneous. Molecular diagnostic methods can provide an additional level of testing that not only helps refine diagnoses but can provide prognostic information. New methods are being refined that may provide information to establish precise diagnostic profiles, provide targets for therapy and provide more sensitive methods for monitoring the success of treatment. Molecular methods will be increasingly utilized and eventually required as the accepted method of diagnosis and for monitoring the disease. Understanding of the molecular abnormality and the pathogenesis of the neoplasm hopefully will lead to therapeutic intervention aimed at the specific molecular defect or its product. The molecular pathology of the non-Hodgkin's lymphomas is discussed.
非霍奇金淋巴瘤涵盖了广泛的血液系统肿瘤,这些肿瘤表现出不同的临床和生物学特征。传统上,淋巴瘤最初是根据其细胞学和组织学特征进行评估的。仅靠形态学往往是不够的,因为外观相似的肿瘤在免疫表型和分子水平上可能是异质性的。分子诊断方法可以提供额外的检测水平,不仅有助于完善诊断,还能提供预后信息。正在完善的新方法可能会提供信息,以建立精确的诊断图谱、提供治疗靶点,并提供更敏感的方法来监测治疗效果。分子方法将越来越多地被使用,最终将成为公认的诊断和监测疾病的方法。对肿瘤分子异常和发病机制的理解有望带来针对特定分子缺陷或其产物的治疗干预。本文将讨论非霍奇金淋巴瘤的分子病理学。